SciCombinator

Discover the most talked about and latest scientific content & concepts.

A Sakuraba, K Keyashian, C Correia, J Melek, RD Cohen, SB Hanauer and DT Rubin
Abstract
: Natalizumab is an efficacious agent for the induction and maintenance of remission in patients with Crohn’s disease (CD) who have failed anti-tumor necrosis factor (TNF) agents. We aimed to assess the efficacy and safety of natalizumab outside of clinical trial at a US tertiary center.
Tweets*
7
Facebook likes*
0
Reddit*
0
News coverage*
0
Blogs*
0
SC clicks
1
Concepts
Effectiveness, Biopsy, Colonoscopy, Inflammation, Gastroenterology, Inflammatory bowel disease, Ulcerative colitis, Crohn's disease
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com